Canada · Health Canada Drug Product Database

LONGAVO

A source-listed medicine record.

Factual source checks only. This page is not a clinically reviewed monograph. Historical or discontinued records may be included; listing does not confirm approval, current availability or pharmacy stock.

Medicine identity

Source reference: 106170
DIN: 02558459
Form: Suspension (Extended-Release)
Company as listed by source: TEVA CANADA LIMITED
Source status: Approved (2025-06-18)
Source last updated: 2026-07-31

Source-listed ingredients

RISPERIDONE — 75 MG — per 0.21 ML

These values do not establish equivalence or a dose recommendation.

Packages

Package details are not available in this snapshot.

Source and coverage

Open Health Canada Drug Product Database →

Snapshot retrieved: 2026-09-17. This is the acquisition date, not a medical review date.

Clinical information, images and comparisons appear only when separately reviewed for this record. Coverage may be incomplete. Ask a pharmacist or clinician about your treatment.

Browse Canada records →